Our objective was to determine the efficacy of a fludarabine (Fludara)/mitoxantrone (Novantrone) regimen combined with the monoclonal anti-CD20 antibody rituximab (Rituxan) to induce clinical and molecular remissions in patients with relapsed
L. Palomera
Advertisement
Articles by L. Palomera
Advertisement
Latest Updated Articles
- Relapsed Follicular Lymphoma: Response to a Fludarabine/Mitoxantrone Regimen and the Monoclonal Anti-CD20 Antibody Rituximab
Published: March 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
5
